NCT02849145View on ClinicalTrials.gov

Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

February 25, 2020

Study Completion Date

February 25, 2020

Conditions
Uveal Melanoma
Interventions
BIOLOGICAL

Blood sampling

7,5 ml of patient peripherical blood will be collected at each blood sample.

Trial Locations (1)

75005

Institut Curie, Paris

All Listed Sponsors
lead

Institut Curie

OTHER

NCT02849145 - Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) | Biotech Hunter | Biotech Hunter